HempFusion Partner With Researchers To Identify New Uses Of Hemp Products
NEW YORK, May 15, 2021 /PRNewswire/ -- The CBD market is estimated to hit the $23.7 billion mark by 2023, with the US likely to be one of the more lucrative markets for hemp-derived CBD products, with almost all states having legalized hemp-derived CBD. Research institutions are also looking into the effects that hemp-derived CBD has on the body.
There is a lot of promise within the medical community. Such research may open up more revenue opportunities if companies are able to make science-backed structure-function claims about the benefits of CBD derived from hemp. Clinical research and studies are also key to informing the FDA's regulatory framework by providing reliable expert data regarding the functioning and effects of hemp-derived CBD products.
HempFusion Wellness Inc. (TSX: CBD-U.TO) (OTC: CBDHF), a health and wellness CBD company, announced that Dr. David Harnick, a prominent Cardiologist and Assistant Professor of Medicine and Cardiology at Mount Sinai Medical Hospital in New York, has chosen the company to be the exclusive provider of products to be used in a six-month clinical trial. The clinical trial consists of two studies conducted by Dr. Harnick.
According to Dr. Harnick, "Studying the potential effects that CBD may have on cardiology markets may potentially unlock some of the scientific mysteries that exist today. We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomized prospective controlled trials evaluating the effects of CBD on these cardiac markets, so this research may prove to be groundbreaking." The study is expected to commence in March 2021 and it will be one-of-a-kind in the area of the effects of CBD on targeted cardiology markers.
Dr. Harnick chose HempFusion for its rigorous regulatory standards, toxicology studies for safety, and adherence to quality control. Dr. Harnick constructed this long-term clinical trial to gather data that will help in the deeper understanding of the effects CBD has on the body.
HempFusion, partnered with ValidCare as a co-sponsor alongside 12 other companies in the CBD space, collaborated in an industry-wide Human Observational liver and male reproductive toxicology study, which explores the effects that full-spectrum hemp-derived CBD has on the liver.
"This is the second clinical trial HempFusion is proudly participating in," HempFusion Wellness CEO Jason Mitchel, N.D. said. "We are committed to furthering research in the area of hemp-derived CBD and this study [with Dr. Harnick] is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products," he added. The CBD used in these trials is the same product the company offers to the public.
.
NEW YORK, May 15, 2021 /PRNewswire/ -- The CBD market is estimated to hit the $23.7 billion mark by 2023, with the US likely to be one of the more lucrative markets for hemp-derived CBD products, with almost all states having legalized hemp-derived CBD. Research institutions are also looking into the effects that hemp-derived CBD has on the body.
There is a lot of promise within the medical community. Such research may open up more revenue opportunities if companies are able to make science-backed structure-function claims about the benefits of CBD derived from hemp. Clinical research and studies are also key to informing the FDA's regulatory framework by providing reliable expert data regarding the functioning and effects of hemp-derived CBD products.
HempFusion Wellness Inc. (TSX: CBD-U.TO) (OTC: CBDHF), a health and wellness CBD company, announced that Dr. David Harnick, a prominent Cardiologist and Assistant Professor of Medicine and Cardiology at Mount Sinai Medical Hospital in New York, has chosen the company to be the exclusive provider of products to be used in a six-month clinical trial. The clinical trial consists of two studies conducted by Dr. Harnick.
According to Dr. Harnick, "Studying the potential effects that CBD may have on cardiology markets may potentially unlock some of the scientific mysteries that exist today. We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomized prospective controlled trials evaluating the effects of CBD on these cardiac markets, so this research may prove to be groundbreaking." The study is expected to commence in March 2021 and it will be one-of-a-kind in the area of the effects of CBD on targeted cardiology markers.
Dr. Harnick chose HempFusion for its rigorous regulatory standards, toxicology studies for safety, and adherence to quality control. Dr. Harnick constructed this long-term clinical trial to gather data that will help in the deeper understanding of the effects CBD has on the body.
HempFusion, partnered with ValidCare as a co-sponsor alongside 12 other companies in the CBD space, collaborated in an industry-wide Human Observational liver and male reproductive toxicology study, which explores the effects that full-spectrum hemp-derived CBD has on the liver.
"This is the second clinical trial HempFusion is proudly participating in," HempFusion Wellness CEO Jason Mitchel, N.D. said. "We are committed to furthering research in the area of hemp-derived CBD and this study [with Dr. Harnick] is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products," he added. The CBD used in these trials is the same product the company offers to the public.
.
Hempfusion Wellness Inc (CBDHF) or (CBD-U.TO) + Frankfurt (CBDHF / CBD-U.TO) Stock Research Links
Robert
